Bristol-Myers Squibb Company

BMY

US1101221083

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

Pharmaceuticals

Calendar

2024-05-07 - Annual General Meeting

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm EST

More Strategies

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

43.99 USD

Average target price

53.19 USD

Spread / Average Target

+20.92%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BRISTOL-MYERS SQUIBB COMPANY	-14.19%	89.17B
ELI LILLY AND COMPANY	+30.83%	662B
NOVO NORDISK A/S	+21.96%	546B
JOHNSON & JOHNSON	-5.26%	359B
MERCK & CO., INC.	+16.88%	323B
ABBVIE INC.	+4.70%	289B
ASTRAZENECA PLC	+13.68%	234B
NOVARTIS AG	+3.81%	198B
ROCHE HOLDING AG	-10.63%	194B
AMGEN INC.	+4.08%	167B

Other Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 02:34:54 2024-05-06 pm EDT			5-day change	1st Jan Change
44 ^USD	+0.03%		-1.37%	-14.19%

02:00pm	Bristol-Myers Squibb Says Applications for Opdivo Accepted by US, European Regulators	MT
01:51pm	Bristol-Myers Gets FDA Acceptance of Review for Subcutaneous Opdivo Formulation	DJ

Bristol-Myers Squibb Says Applications for Opdivo Accepted by US, European Regulators	08:00am	MT
Bristol-Myers Gets FDA Acceptance of Review for Subcutaneous Opdivo Formulation	07:51am	DJ
Bristol-Myers: BLA accepted for subcutaneous Opdivo	07:46am	CF
HSBC Adjusts Price Target on Bristol-Myers Squibb to $45 From $50	May. 01	MT
Editas Medicine, Bristol-Myers Squibb Extend Alpha-Beta T Cell Collaboration	May. 01	MT
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration	May. 01	CI
Global markets live: Adidas, Mercedes, McDonalds, Eli Lilly, PayPal, MicroStrategy, Tesla...	Apr. 30
A flurry of corporate results ahead of the Fed's rate decision	Apr. 30
ANALYST RECOMMENDATIONS : Tesla, Snap, Alphabet, Microsoft, Anglo American...	Apr. 30
Scenic Biotech Enters into Research Collaboration with Bristol Myers Squibb	Apr. 30	CI
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion	Apr. 30	RE
J&J, Bristol Myers lose challenges to US drug price negotiation program	Apr. 29	RE
Goldman Sachs Cuts Bristol-Myers Squibb's Price Target to $56 From $60	Apr. 29	MT
Deutsche Bank Adjusts Price Target on Bristol-Myers Squibb to $53 From $55, Keeps Hold Rating	Apr. 29	MT
Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases	Apr. 29	CI
S&P 500 Q1 earnings estimated growth improves; stocks up for week	Apr. 26	RE
Leerink Partners Cuts Price Target on Bristol-Myers Squibb to $47 From $51	Apr. 26	MT
UBS Cuts Bristol-Myers Squibb Price Target to $47 From $52, Maintains Neutral Rating	Apr. 26	MT
Barclays Adjusts Price Target on Bristol-Myers Squibb to $43 From $51	Apr. 26	MT
JPMorgan Adjusts Bristol-Myers Squibb's Price Target to $60 From $65	Apr. 26	MT
Bristol-Myers Squibb Says European Regulator Recommends Approval of Bladder Cancer Combination Therapy	Apr. 26	MT
Bristol Myers: positive opinion from the CHMP for Opdivo	Apr. 26	CF
Bristol Myers Gets CHMP Backing for Opdivo Combo in Bladder Cancer	Apr. 26	DJ
Morgan Stanley Adjusts Price Target on Bristol-Myers Squibb Company to $37 From $40	Apr. 26	MT
Truist Cuts Price Target on Bristol-Myers Squibb to $64 From $68, Keeps Buy Rating	Apr. 26	MT